The DOI matches its Crossref record; 458 of the 462 references it cites were found in a registry or an index.
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Open accessAbstract
Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse inhibition of startle, exploratory behavior, and interval timing. Many recent clinical trials have yielded important new findings regarding the psychopharmacology of these substances. Furthermore, the use of modern imaging and electrophysiological techniques is beginning to help unravel how hallucinogens work in the brain. Evidence is also emerging that hallucinogens may possess therapeutic efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A default mode of brain function
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.676 · Cited by 12,190 · cited 1×
“…that psilocybin reduces activity and connectivity in core nodes of the default-mode network, brain regions that are active during the resting state and potentially involved in introspective processes (for more information, see: Raichle et al., 2001; Mason et al., 2007; Buckner et al., 2008).”
BackgroundThe Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761 · cited 2×
“…that psilocybin reduces activity and connectivity in core nodes of the default-mode network, brain regions that are active during the resting state and potentially involved in introspective processes (for more information, see: Raichle et al., 2001; Mason et al., 2007; Buckner et al., 2008).”
BackgroundResultParallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527 · cited 1×
“CSTC loops are parallel, anatomically segregated circuits relaying information between the basal ganglia, thalamus, and cortex (Alexander et al., 1986, 1990).”
BackgroundLeDoux, J. E. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.155 · Cited by 8,444
Neuronal Oscillations in Cortical Networks
Buzsáki, G., & Draguhn, A. (2004) · Science · doi:10.1126/science.1099745 · Cited by 6,576 · cited 2×
“Since cortical oscillations play a fundamental role in a diverse set of mental processes and are required for the coordination of neural processing (Gray et al., 1989; Singer, 1999; Buzsaki and Draguhn, 2004; Sejnowski and Paulsen, 2006; Fries, 2009; Klimesch, 2012), it is tempting to speculate that the reduction of n…”
BackgroundNeurophysiological investigation of the basis of the fMRI signal
Logothetis, N. K., Pauls, J., Augath, M., Trinath, T., & Oeltermann, A. (2001) · Nature · doi:10.1038/35084005 · Cited by 6,551 · cited 1×
“One potential explanation is that the hemodynamic responses measured by fMRI are actually better correlated with cortical oscillatory activity than with neuronal firing (Mathiesen et al., 1998; Logothetis et al., 2001; Behav Brain Res.”
BackgroundGray, C. M., König, P., Engel, A. K., & Singer, W. (1989) · Nature · doi:10.1038/338334a0 · Cited by 4,183 · cited 2×
“Since cortical oscillations play a fundamental role in a diverse set of mental processes and are required for the coordination of neural processing (Gray et al., 1989; Singer, 1999; Buzsaki and Draguhn, 2004; Sejnowski and Paulsen, 2006; Fries, 2009; Klimesch, 2012), it is tempting to speculate that the reduction of n…”
BackgroundThalamocortical oscillations in the sleeping and aroused brain
Steriade, M., McCormick, D. A., & Sejnowski, T. J. (1993) · Science · doi:10.1126/science.8235588 · Cited by 3,564 · cited 1×
“Under anesthesia or during slow-wave sleep, cortical networks display slow (0.5–1 Hz) and delta (1–4 Hz) oscillations (Steriade et al., 1993a,b; Steriade, 1997) that reflect alternations between periods of silence (DOWN states) and periods of depolarization with repetitive spiking (UP states).”
BackgroundInfluentialAlpha-band oscillations, attention, and controlled access to stored information
Klimesch, W. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2012.10.007 · Cited by 3,310 · cited 2×
“Since cortical oscillations play a fundamental role in a diverse set of mental processes and are required for the coordination of neural processing (Gray et al., 1989; Singer, 1999; Buzsaki and Draguhn, 2004; Sejnowski and Paulsen, 2006; Fries, 2009; Klimesch, 2012), it is tempting to speculate that the reduction of n…”
BackgroundInternational Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. A. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 3,025 · cited 2×
“The 5-HT2 receptor class was later reorganized to include three subtypes: 5-HT2A (equivalent to the site known historically as the 5-HT2 receptor or the D receptor), 5-HT2B (formerly known as the 5HT2F receptor), and 5-HT2C (formerly known as the 5-HT1C receptor) (Hoyer et al., 1994).”
Background
Flagged first, then by citations
4 of the 462 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- Glennon, 1982, The use of the drug discrimination paradigm for studying hallucinogenic agents. A review, 69
- Dittrich, 1975, Zusammenstellung eines Fragebogens (APZ) zur Erfassung abnormer psychischer Zustände, Z Klin Psychol Psychother, 23, 12
- Young, 1981, The hallucinogen DOM as a discriminative stimulus, Commun Psychopharmacol, 4, 501
- Glennon, 1985, Site-selective 5-HT agonists as discriminative stimuli, Pharmacologist, 27, 194
- Serko, 1913, Im Mescalinrausch, Jahrb Psychiatr Neurol, 31, 355
- Prentiss, 1895, Anhalonium lewinii (mescal buttons): a study of the drug, with especial reference to its physiological action upon man, with report of experiments, Ther Gaz, 19, 577
- Ellis, 1898, Mescal: a new artificial paradise, Annu Rep Smithsonian Inst, 537
Cited by
Sorted by citations
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
“The classic hallucinogens, which include psilocybin (psilocin) and (+)-lysergic acid diethylamide (LSD), are a structurally diverse group of compounds that are 5-HT2A receptor agonists and produce a unique profile of changes in thoughts, perceptions, and emotions (Halberstadt, 2015; Nichols, 2016).”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
“In the study byHalberstadt et al. (2011a), the response to psilocin was not affected by deletion of the 5-HT2A receptor gene.”
BackgroundMethodInfluentialNeural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
“LSD has a high affinity for a range of different neurotransmitter receptors, but its characteristic psychological effects are thought to be mediated by serotonin 2A receptor (5-HT2AR) agonism (7).”
BackgroundSerotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“…this limitation, we also wish to emphasise that the evidence is compelling that 5-HT2AR agonism is key to psychedelics’ most characteristic effects (Halberstadt, 2015), 5-HT1AR agonism attenuates rather than augments these effects (Pokorny et al., 2016; Strassman, 1996) and more selective 5-HT2AR…”
BackgroundBogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
Psychedelics, meditation, and self-consciousness
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01475 · Cited by 390
“Classic psychedelics, also known as classic hallucinogens, are a family of psychoactive substances that exert their subjective effects primarily by agonism (or partial agonism) of serotonin 2A (5-HT2A) receptors (Halberstadt, 2015; Nichols, 2016).”
BackgroundIncreased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K., & Muthukumaraswamy, S. D. (2017) · Scientific Reports · doi:10.1038/srep46421 · Cited by 410
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
“The pharmacological profiles of psilocin and LSD are particularly interesting because both substances currently receive high interest as research tools and potential therapeutic substances in psychiatry (Geyer, 2015; Halberstadt, 2015; Kupferschmidt, 2014).”
Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366
“…acid diethylamide (LSD), mescaline, and dimethyltryptamine (DMT; contained in the sacramental beverage ayahuasca) share a primary pharmacological site of action at the serotonin 2a (5HT2a) receptor, and display striking similarities in their subjective effects (Halberstadt, 2015; Nichols, 2016).”
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 359
“Today, research has repeatedly shown that psychedelics do not cause dependence or compulsive use (Halberstadt, 2015; Johnson et al., 2018; Morgenstern et al., 1994; Nichols, 2016).”
BackgroundNovel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 330
“LSD, psilocybin and mescaline are all classical serotonergic psychedelics with main mechanism of action at the 5-HT2A receptor (Halberstadt, 2015).”
BackgroundHallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
López‐Giménez, J. F., & González‐Maeso, J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_478 · Cited by 325
“Recent findings have elucidated additional neuronal signaling pathways downstream from the 5-HT2A receptor that is potentially involved in the unique behavioral effects induced by hallucinogens (Halberstadt 2015; Hanks and Gonzalez-Maeso 2013).”
BackgroundHalberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
“All three of the behavioral effects included in the present investigation (HTR in mice, hallucinogen discriminative stimulus effects in rats, and psyche-delic effects in humans) have been linked to 5-HT 2A activation (Halberstadt, 2015; Nichols, 2016).”
Self-citationNeuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
“Stimulation of phospholipase A2 does not seem to directly related to the subjective effects of psychedelic compounds (Halberstadt, 2015; Kurrasch-Orbaugh et al., 2003).”
BackgroundBarnes, N. M., Ahern, G. P., Bécamel, C., Bockaert, J., Camilleri, M., Chaumont‐Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C. F., Gershon, M. D., et al. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 274
Self-citationInclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature.
Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1824-6 · Cited by 265
“Behavioral Pattern Monitor (BPM) studies in rats have shown that psychedelics exhibit a distinguishable profile of behavioral effects analogous to the enhanced sensitivity and reactivity to environmental stimuli that occurs in humans [55].”
BackgroundClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
“It has been proposed that the PET study findings of hyperfrontality reflect the increased neuronal firing activity while fMRI BOLD measures correlate with cortical oscillatory activity (Halberstadt, 2015).”
BackgroundCentral 5-HT receptors and their function; present and future
Sharp, T., & Barnes, N. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108155 · Cited by 239
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
“…they are thought to exert their primary effects primarily through agonist or partial agonist activity at serotonin 2A (5HT2A) receptors, and that they substitute for the prototypical classic hallucinogen 2,5-dimethoxy-4-methylamphetamine (DOM) in drug discrimination experiments (Halberstadt, 2015).”
InfluentialPsychedelics, personality and political perspectives.
Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1312643 · Cited by 226
Rickli, A., Luethi, D., Reinisch, J., Buchy, D., Hoener, M. C., & Liechti, M. E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.034 · Cited by 215
“, 1997), suggesting that additional ligandereceptor interactions contribute to receptor activation (Halberstadt, 2015; Nichols, 2004).”
BackgroundInfluentialDeco, G., Cruzat, J., Cabral, J., Knudsen, G. M., Carhart-Harris, R. L., Whybrow, P. C., Logothetis, N. K., & Kringelbach, M. L. (2018) · Current Biology · doi:10.1016/j.cub.2018.07.083 · Cited by 211
“It has been suggested that the 5-HT1A receptor also contributes to the effects of LSD [22, 32], and indeed, this is confirmed by the improved performance of the 5-HT1A receptor-binding map compared to the 5-HT1B, 5-HT4, and 5-HTT maps [22].”
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“LSD acts primarily as a serotonergic agonist, but also shows action at dopaminergic and adrenergic receptor sites (Halberstadt, 2015; Nichols, 2004).”
BackgroundUnifying Theories of Psychedelic Drug Effects
Swanson, L. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00172 · Cited by 194
“A molecule’s propensity for 5-HT2A affinity and agonist activity predicts its potential for (and potency of) subjective psychedelic effects (Glennon et al., 1984; McKenna et al., 1990; Halberstadt, 2015; Nichols, 2016; Rickli et al., 2016).”
BackgroundIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potential
Wallach, J. V., Cao, A. B., Calkins, M. M., Heim, A. J., Lanham, J. K., Bonniwell, E. M., Hennessey, J. J., Bock, H. A., Anderson, E. I., Sherwood, A. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44016-1 · Cited by 193
Self-citationDreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
Krähenmann, R., Pokorný, D., Vollenweider, L., Preller, K. H., Pokorny, T., Seifritz, E., & Vollenweider, F. X. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4610-0 · Cited by 187
Yanakieva, S., Polychroni, N., Family, N., Williams, L. T. J., Luke, D. P., & Terhune, D. B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5119-x · Cited by 174
“Insofar as there is substantial evidence that LSD alters psychological functions by targeting 5-HT2A receptors (Halberstadt 2015; López-Giménez and González-Maeso 2018; Nichols 2016; Preller et al. 2017), one possible outcome was that microdoses of LSD would produce temporal underreproduction, as…”
Millière, R. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00245 · Cited by 206
“While their immediate effects on perception and mood are well-documented (Halberstadt, 2015), some of their complex effects at higher doses have received less attention until more recently.”
BackgroundInfluentialExploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchar, M., Sjoerds, Z., & Hommel, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5049-7 · Cited by 177
“Of particular interest in this regard are findings from animal studies showing that 5- HT2A agonist activity (Halberstadt 2015) correlates with an increase in associative learning (Harvey et al. 2003) and improvements in the ability to adapt behavior more flexibly (Boulougouris et al. 2008).”
BackgroundTaves, A. (2020) · Perspectives on Psychological Science · doi:10.1177/1745691619895047 · Cited by 140
“There has been a flurry of research in recent years using both neuroimaging and experimental methods to investigate the neural correlates of experiences induced by psychoactive drugs, including ego dissolution (for indepth reviews of this body of research, see dos Santos, Osório, Crippa, & Hallak, 2016; Halberstadt, 2…”
BackgroundInfluentialA non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Lewis, V., Bonniwell, E. M., Lanham, J. K., Ghaffari, A., Sheshbaradaran, H., Cao, A. B., Calkins, M. M., Bautista-Carro, M. A., Arsenault, E., Telfer, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112203 · Cited by 156
Self-citationZebrafish neurobehavioral phenomics for aquatic neuropharmacology and toxicology research
Kalueff, A. V., Echevarria, D. J., Homechaudhuri, S., Stewart, A., Collier, A. D., Kaluyeva, A. A., Li, S., Liu, Y., Chen, P., Wang, J., et al. (2015) · Aquatic Toxicology · doi:10.1016/j.aquatox.2015.08.007 · Cited by 129
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
“In addition, psilocybin has a short acute window of 2–6 h, which contributes to more manageable and inexpensive clinical trials, differing greatly from mescaline and LSD with acute windows of 6–8 h and 8–20 h, respectively [27, 28].”
BackgroundReiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majić, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.012 · Cited by 122
“Moreover, psychedelics share a common mechanism of action at different 5-HT receptors, primarily the 5-HT2A receptor (Geyer and Vollenweider, 2008), which appears to be crucial for the specific psycho-vegetative effects, probably by activating a complex signal cascade (Halberstadt, 2015; Vollenweider and Kometer, 2010…”
BackgroundDark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 128
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis
Roméo, B., Karila, L., Martelli, C., & Benyamina, A. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120919957 · Cited by 122
“Indeed, these drugs have an action on the serotoninergic system by a 5-HT1A/2A/2C agonism (Halberstadt, 2015).”
BackgroundClassic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 119
“LSD and other ergolines also act upon dopaminergic (D1, D2) and adrenergic receptors [4], while mescaline and DOI are selective agonists at 5-HT2A, 5-HT2B, and 5-HT2C sites [81].”
Effect of Hallucinogens on Unconditioned Behavior
Halberstadt, A. L., & Geyer, M. A. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_466 · Cited by 117
“Most importantly, as we have reviewed elsewhere (Halberstadt 2015), manipulations that suppress recurrent glutamatergic network activity also block the HTR.”
BackgroundSelf-citationInvestigation of the Structure–Activity Relationships of Psilocybin Analogues
Klein, A. K., Chatha, M., Laskowski, L. J., Anderson, E. I., Brandt, S. D., Chapman, S. J., McCorvy, J. D., & Halberstadt, A. L. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00176 · Cited by 103
Self-citationPharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens
Halberstadt, A. L. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_64 · Cited by 104
Self-citationDevelopment of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Bogenschutz, M. P., & Forcehimes, A. A. (2016) · Journal of Humanistic Psychology · doi:10.1177/0022167816673493 · Cited by 102
“The primary molecular target of all classic hallucinogens is thought to be the serotonin 2A (5HT2A) receptor (Halberstadt, 2015; Nichols, 2004), which is rapidly down-regulated following hallucinogen administration.”
BackgroundClassical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
“…action of these compounds (Vollenweider et al., 1998; Hintzen and Passie, 2010; Vollenweider and Kometer, 2010; Kometer et al., 2012, 2013; Hanks and González-Maeso, 2013; Baumeister et al., 2014; Tylš et al., 2014; Halberstadt, 2015; Nichols, 2016; Valle et al., 2016; Tagliazucchi et al., 2016).”
Legally flawed, scientifically problematic, potentially harmful: The UK Psychoactive Substance Bill
Stevens, A., Fortson, R., Measham, F. C., & Sumnall, H. R. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.10.005 · Cited by 97
Chi, T., & Gold, J. A. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116715 · Cited by 95
Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Kraehenmann, R. (2017) · Current Neuropharmacology · doi:10.2174/1573413713666170619092629 · Cited by 92
“3The psychoactive effects of classical, or serotonergic psychedelics are commonly mediated via activation of central serotonin 2A (5HT2A) receptors [7]; classical psychedelics include the indoleamines such as dimethyltryptamine (DMT), psilocybin (4-phosphoryloxy-DMT), and lysergic acid diethylamide (LSD); and the phen…”
BackgroundInfluentialMeinhardt, M. W., Pfarr, S., Fouquet, G., Rohleder, C., Meinhardt, M. L., Barroso-Flores, J., Hoffmann, R., Jeanblanc, J., Paul, E., Wagner, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2399 · Cited by 89
“Psilocybin intraperitoneal treatment restored Grm2 expression (F[1,16] = 8.”
BackgroundResultMartin, D. A., & Nichols, C. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.049 · Cited by 93
“Although many psychedelics exhibit complex receptor pharmacology (Halberstadt and Geyer, 2011; Nichols, 2016), all are believed to exhibit their primary effects through activation of the brain serotonin 5-HT2A receptor (Glennon et al., 1984; Halberstadt, 2015) in both humans (Vollenweider et al.”
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 96
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., Wallach, J. V., & Halberstadt, A. L. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1884 · Cited by 81
Self-citationDuan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 81
Romeo, B., Hermand, M., Pétillion, A., Karila, L., & Benyamina, A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.002 · Cited by 76
“This agonism, particularly the 5-HT2A agonism, could provoke a glutamate release leading to an activation of the fronto-cortical glutamate receptor (Halberstadt, 2015).”
BackgroundMicrodosing psychedelics: Demographics, practices, and psychiatric comorbidities
Rosenbaum, D., Weissman, C., Anderson, T., Petranker, R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120908004 · Cited by 76
“…that share 5-HT2A receptor agonist properties, and which, at higher doses, induce profound alterations in thought, perception, and emotion (Halberstadt, 2015; Nichols, 2016; Rickli et al., 2016), along with experiences of ego dissolution (Letheby and Gerrans, 2017; Milliere, 2017), and/or…”
BackgroundDipasquale, O., Selvaggi, P., Veronese, M., Gabay, A. S., Turkheimer, F., & Mehta, M. A. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.007 · Cited by 71
“It can also produce mild visual hallucinatory phenomena, which have been linked to the 5-HT2A receptor, the same receptor targeted by the classic psychedelics (Gouzoulis-Mayfrank et al., 1996; Harris et al., 2002; Liechti and Vollenweider, 2001).”
Biosynthesis and synthetic biology of psychoactive natural products
Jamieson, C. S., Misa, J., Tang, Y., & Billingsley, J. M. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00065a · Cited by 74
Positive regulation of raphe serotonin neurons by serotonin 2B receptors
Belmer, A., Quentin, E., Diaz, S. L., Guiard, B. P., Fernández, S. P., Doly, S., Banas, S. M., Pitychoutis, P. M., Moutkine, I., Muzerelle, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0013-0 · Cited by 67
“Here, we tested ±DOI at 1, 3, and 5mg/kg i.p.”
BackgroundInfluentialRaut, S. B., Marathe, P. A., van Eijk, L., Eri, R. D., Ravindran, M., Benedek, D. M., Ursano, R. J., Canales, J. J., & Johnson, L. R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108195 · Cited by 74
New therapeutic opportunities for 5-HT2 receptor ligands
Maroteaux, L., Ayme‐Dietrich, E., Aubertin-Kirch, G., Banas, S. M., Quentin, E., Lawson, R., & Monassier, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.008 · Cited by 66
The serotonin 5-HT 2C receptor and the non-addictive nature of classic hallucinogens
Canal, C. E., & Murnane, K. S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677104 · Cited by 73
“Classic hallucinogens (CH) are powerful psychoactive substances that are categorized into two broad chemotype classes: indoleamines (including tryptamines and ergotamines) and phenylalkylamines (including phenethylamines and phenylisopropylamines; Halberstadt, 2015).”
InfluentialThe epistemic innocence of psychedelic states
Letheby, C. (2016) · Consciousness and Cognition · doi:10.1016/j.concog.2015.11.012 · Cited by 67
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
Kantrowitz, J. T. (2020) · CNS Drugs · doi:10.1007/s40263-020-00752-2 · Cited by 68
Jensen, A. A., McCorvy, J. D., Leth‐Petersen, S., Bundgaard, C., Liebscher, G., Kenakin, T., Bräuner‐Osborne, H., Kehler, J., & Kristensen, J. L. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.239905 · Cited by 65
“However, in recent years the remarkable effects mediated by LSD and psilocybin in rodent models of cognitive and psychiatric disorders and in human treatment trials of depression, posttraumatic stress, obsessive-compulsive disorder, autism, and various forms of addiction have substantiated this potential and rekindled…”
BackgroundAtasoy, S., Vohryzek, J., Deco, G., Carhart-Harris, R. L., & Kringelbach, M. L. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.009 · Cited by 59
DARK Classics in Chemical Neuroscience: NBOMes
Poulie, C. B. M., Jensen, A. A., Halberstadt, A. L., & Kristensen, J. L. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00528 · Cited by 68
Self-citationPsychedelics as a Treatment for Alzheimer’s Disease Dementia
Jones, S. V., & O’Kelly, A. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00034 · Cited by 68
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
“Indeed, 5-HT2C and 5-HT1A receptors may also play a role (see reviews by Nichols 2004, 2016; Halberstadt 2015; Carbonaro and Gatch 2016) as well as other known and, perhaps, unknown receptors or compounds yet to be identified in what may be a far more complex system than we know.”
BackgroundLeón, L. A., Gomes, V. D. C., Zárate-Guerrero, S., Corredor, K., Cruz, A. P. D. M., Brandão, M. L., Cárdenas, F. P., & Landeira-Fernández, J. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00117 · Cited by 60
“…is excitatory and appears to mediate depolarizing effects (Davie et al., 1988; Eison and Mullins, 1996; Hasuo et al., 2002), but it may also have inhibitory activity or even interact with a number of other inhibitory interneurons (Avesar and Gulledge, 2012; Halberstadt, 2015; Wang et al., 2016).”
BackgroundSmausz, R., Neill, J. C., & Gigg, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221092508 · Cited by 65
“Created with BioRender.com. psychedelic state in rodents, is completely blocked by 5HT2A-R antagonists (Halberstadt, 2015).”
BackgroundRoseman, L., Sereno, M. I., Leech, R., Kaelen, M., Orbán, C., McGonigle, J., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23224 · Cited by 59
“It is assumed that LSD’s principal “psychedelic” effects are mediated by activation of serotonin 2A receptor (5-HT2AR) [Halberstadt, 2014].”
Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives
Pallavicini, C., Vilas, M. G., Villarreal, M. F., Zamberlán, F., Muthukumaraswamy, S. D., Nutt, D., Carhart-Harris, R. L., & Tagliazucchi, E. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.06.053 · Cited by 60
Brandt, S. D., Kavanagh, P. V., Twamley, B., Westphal, F., Elliott, S. P., Wallach, J. V., Stratford, A., Klein, L. M., McCorvy, J. D., Nichols, D. E., et al. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2222 · Cited by 58
Self-citationOña, G., & Bouso, J. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.035 · Cited by 60
Aqil, M., & Roseman, L. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109300 · Cited by 63
“These substances elicit an extremely varied array of effects, spanning the entire brain functional hierarchy, from low-level sensory, to mood, and high-level cognitive alterations (Halberstadt, 2015; Nichols, 2016; Preller and Vollenweider, 2016; Kyzar et al., 2017; Vollenweider and Preller, 2020; Inserra et al., 2021…”
Backgrounddos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
“Several receptor-level and molecular studies have shown that 5-HT1A/2C receptors play a role in the effects of psychedelics (Halberstadt, 2015; Marek, 2018; Nichols, 2004, 2016).”
BackgroundElmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.033 · Cited by 58
“One class of serotonergic hallucinogens is the phenylalkylamines, which can be further divided into phenylisopropylamines like 1-(4-iodo-2,5-dimethoxyphenyl) propan-2-amine (DOI) and phenethylamines like 2-(4-iodo-2,5dimethoxyphenyl)ethanamine (2C-I) (Halberstadt, 2015) (see Fig.”
BackgroundSafety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115880 · Cited by 69
Metabolism of lysergic acid diethylamide (LSD): an update
Libânio Osório Marta, R. F. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1638931 · Cited by 54
“Their main mechanism of action is based on an agonist (or partial agonist) action at serotonin (5-HT)2A receptors (Rickli et al. 2016), which explains the unique and powerful ability of hallucinogens to affect the human psyche (Halberstadt 2015; Preller et al. 2017).”
BackgroundClassic psychedelics and alcohol use disorders: A systematic review of human and animal studies
Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 58
Wolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 51
“Although the psychedelic drugs LSD, psilocybin, and mescaline are derived from structurally distinct chemical entities, their hallucinogenic effect is similar [80, 81] and primarily mediated through 5-HT2A receptors [82].”
BackgroundLysergic acid diethylamide: a drug of ‘use’?
Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316640440 · Cited by 53
“5HT2A receptor activation is coupled with several intracellular signaling pathways [Halberstadt, 2015].”
Sexton, J. D., Nichols, C. D., & Hendricks, P. S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00896 · Cited by 46
Klein, L. M., Cozzi, N. V., Daley, P. F., Brandt, S. D., & Halberstadt, A. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.028 · Cited by 45
“Over the past decade there has been a renewed focus on the pharmacology and effects of serotonergic hallucinogens (Halberstadt, 2015; Nichols, 2016).”
Self-citationHerian, M., Wojtas, A., Kamińska, K., Świt, P., Wach, A., & Gołembiowska, K. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00033-x · Cited by 44
“5-HT2A receptors are highly expressed on glutamatergic pyramidal neurons and GABAergic basket and chandelier cells in layer Vof the prefrontal cortex (Halberstadt 2015).”
BackgroundGrafinger, K. E., Liechti, M. E., & Liakoni, E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14115 · Cited by 45
Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice
Halberstadt, A. L., Sindhunata, I. S., Scheffers, K., Flynn, A. D., Sharp, R. F., Geyer, M. A., & Young, J. W. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.038 · Cited by 43
“Hallucinogens induce their characteristic effects by activating 5-HT2A receptors (Nichols 2004; Halberstadt, 2015), but it remains to be determined whether their effects on temporal perception are mediated by 5-HT2A.”
BackgroundSelf-citationVejmola, Č., Tylš, F., Piorecká, V., Koudelka, V., Kadeřábek, L., Novák, T., & Páleníček, T. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01603-4 · Cited by 50
“Despite the structural difference, they produce very similar effects, which are mediated mainly via their agonistic action on 5-HT2A receptors [5, 6].”
BackgroundNovel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190312102444 · Cited by 44
Eleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39
““Classical” serotonergic psychedelics, including psilocybin and LSD, act as agonists on the serotonin system, with relative selectivity for the 5HT2A receptor (24), whilst dissociative psychedelics, such as ketamine, hijack the glutamatergic system, acting as NMDAR antagonists (25).”
BackgroundBarrett, F. S., Schlienz, N. J., Lembeck, N. A., Waqas, M., & Vandrey, R. G. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0052 · Cited by 41
“gic acid diethylamide, and dimethyltryptamine [DMT]) are altered perception and cognition,(3) mystical or spiritual experiences,(4,5) and occasional anxiety and physiological distress,(6) and the molecular mechanism of action of hallucinogens is understood to be 5HT2A receptor agonism.(7,8) A set of pharmacologically…”
BackgroundPsilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Thomas, C. W., Blanco‐Duque, C., Bréant, B. J. B., Goodwin, G. M., Sharp, T., Bannerman, D. M., & Vyazovskiy, V. V. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01846-9 · Cited by 49
Yu, C., Liang, C., Yang, F., Tu, Y., Hsu, C., Carvalho, A. F., Stubbs, B., Thompson, T., Tsai, C., Yeh, T., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040938 · Cited by 40
“It is a 5-HT2a receptor agonist that causes distortions in perception, thoughts, and emotions, as well as self-boundary dissolution [1].”
BackgroundLSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice
Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00994 · Cited by 38
“…hallucinogens” (Nichols, 2004), “serotonergic hallucinogens” Frontiers in Pharmacology | www.frontiersin.org 1 August 2018 | Volume 9 | Article 994 (Halberstadt, 2015), or “psychedelics” (Nichols, 2016), are reported to be effective in some clinical studies of AUD (Krebs and Johansen, 2012;…”
BackgroundDesign and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists.
Cheng, J.-J., McCorvy, J., Giguère, P., Zhu, H., Kenakin, T., Roth, B., & Kozikowski, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01194 · Cited by 34
Halberstadt, A. L., Chatha, M., Klein, A. K., McCorvy, J. D., Meyer, M. R., Wagmann, L., Stratford, A., & Brandt, S. D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107856 · Cited by 38
“Given the difficulties associated with hallucinogen studies in humans, animal behavioral models have been widely used to investigate the pharmacology of serotoninergic hallucinogens (Halberstadt 2015; Halberstadt and Geyer 2018).”
BackgroundMethodSelf-citationPottie, E., & Stove, C. P. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15570 · Cited by 37
“Serotonergic psychedelics or classic hallucinogens are described as substances capable of altering thought, perception, and mood, without memory impairment, delirium, or addiction, with activation of the serotonin (5- HT) 2A receptor (5- HT2AR) as a main pharmacological mechanism (Glennon et al., 1984; Halberstadt, 20…”
BackgroundInfluential
Metadata
- Authors
- Halberstadt, A. L.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Halberstadt, Adam L.
- ORCID
- Halberstadt, Adam L.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 277
- Pages
- 99-120
- ISSN
- 0166-4328 (ISSN-L)
- PMC
- PMC4642895
- OpenAlex
- W2052466574
- Semantic Scholar
- 09d1ad0158732c17a145c95ba0ac4f6ed7bdf021
- Cited by
- 312
- References
- 462
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 21 · 2022: 33 · 2021: 35 · 2020: 27 · 2019: 17 · 2018: 28 · 2017: 26 · 2016: 27 · 2015: 12
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Behavioural Brain Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIMH (K01 MH100644)
- NIDA (R01 DA002925)
- Brain and Behavior Research Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- serotonergic hallucinogens, 5-HT2A receptor, lysergic acid diethylamide, psilocybin, mescaline, cross-tolerance, drug discrimination, head-twitch response, exploratory behavior, interval timing, electrophysiology
- MeSH terms
- Animals, Behavior, Animal, Brain, Exploratory Behavior, Hallucinogens, Humans, Lysergic Acid Diethylamide, Receptor, Serotonin, 5-HT2A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review